$4.19 Billion is the total value of Rock Springs Capital Management LP's 121 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 27.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMCR | Sell | IMMUNOCORE HLDGS PLCads | $148,402,169 | -21.7% | 3,001,662 | -9.6% | 3.54% | -22.4% |
| PEN | Sell | PENUMBRA INC | $120,812,115 | +6.9% | 433,500 | -14.7% | 2.88% | +5.9% |
| ALGN | Sell | ALIGN TECHNOLOGY INC | $82,649,529 | +29.6% | 247,350 | -18.2% | 1.97% | +28.6% |
| AGIO | Sell | AGIOS PHARMACEUTICALS INC | $61,137,067 | -27.3% | 2,661,605 | -11.2% | 1.46% | -28.0% |
| RYTM | Sell | RHYTHM PHARMACEUTICALS INC | $28,492,674 | -44.4% | 1,597,123 | -9.3% | 0.68% | -44.9% |
| COLL | Sell | COLLEGIUM PHARMACEUTICAL INC | $15,593,500 | -7.3% | 650,000 | -10.3% | 0.37% | -8.1% |
| Sell | DISC MEDICINE INC | $6,642,387 | -1.6% | 313,468 | -7.7% | 0.16% | -2.5% | |
| GMDA | Sell | GAMIDA CELL LTD | $1,899,166 | -64.3% | 2,344,649 | -43.1% | 0.04% | -64.8% |
| FSTX | Exit | F-STAR THERAPEUTICS INC | $0 | – | -751,889 | -100.0% | -0.11% | – |
| Exit | CINCOR PHARMA INC | $0 | – | -1,116,578 | -100.0% | -0.33% | – | |
| BAX | Exit | BAXTER INTL INC | $0 | – | -1,150,000 | -100.0% | -1.41% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.